Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04543253 · ClinicalTrials.gov registry record
Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)
A clinical trial of Cushing Syndrome, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 700
- Enrollment target
- 1
- Study location
NCT04543253: Recruiting study of Cushing Syndrome, sponsored by Mayo Clinic.
NCT04543253 is a study of Cushing Syndrome that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 700 participants, above the 103-participant average among 9 other Cushing Syndrome trials with a reported enrollment target (580% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04543253, a study of Cushing Syndrome, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 700 participants
- Enrollment target
- 1
- Study location
Study Summary
Cushing syndrome (CS) is an endocrine disorder caused by chronic exposure to glucocorticoid (GC) excess. Endogenous CS has an estimated incidence of 0.2 to 5.0 cases per million per year and prevalence of 39 to 79 cases per million in various populations. CS usually affects young women, with a median age at diagnosis of 41.4 with a female-to-male ratio of 3:1. Following a curative surgery for CS, patients develop adrenal insufficiency and require GC replacement postoperatively until the hypothalamic-pituitary-adrenal (HPA) axis recovery occurs. Factors, such as age, gender, BMI, subtypes of CS, duration of symptoms, clinical and biochemical severity and postoperative GC dose have been reported to affect the HPA recovery in small retrospective studies. Glucocorticoid withdrawal syndrome (GWS) is a withdrawal reaction due to decrease in supraphysiological GC concentrations, which occurs after a successful surgery of CS. Glucocorticoid withdrawal syndrome (GWS) is under-recognized entity in patients undergoing curative surgery for endogenous Cushing syndrome. In this study we aim to determine pre- and post-surgical predictors of the duration and severity of glucocorticoid withdrawal in patients undergoing a curative surgery for cortisol excess and assess the effect of MUSE intervention on GWS severity in patients undergoing curative surgery for CS as compared to standard of care.
Primary Outcome
Score 0-100
Conditions Studied
Interventions
- OTHER MUSE biofeedback
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2019-07-25 |
| Est. Completion | 2030-12 |
What NCT04543253 shows while recruiting
NCT04543253 is an observational study that tracks outcomes without assigning an intervention. The registered 700 participants enrollment target is mid-sized for trials with a published cap, above the 103-participant average among 9 other Cushing Syndrome trials with a reported enrollment target (580% higher).
The record links to 1 condition, with Cushing Syndrome appearing as the primary indexed condition, and to 1 intervention - of which MUSE biofeedback is the first listed.
NCT04543253 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT04543253 about?
NCT04543253 is a clinical study titled "Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)". Cushing syndrome (CS) is an endocrine disorder caused by chronic exposure to glucocorticoid (GC) excess. Endogenous CS has an estimated incidence of 0.2 to 5.0 cases per million per year and prevalence of 39 to 79 cases per million in various populations. CS usually affects young women, with a media...
What is the current status of trial NCT04543253?
This trial is currently recruiting. The enrollment target is 700 participants. The study started on 2019-07-25. Estimated completion is 2030-12.
What conditions does trial NCT04543253 study?
This clinical trial studies the following conditions: Cushing Syndrome.
What interventions are being tested in trial NCT04543253?
The interventions under investigation include: MUSE biofeedback (OTHER).
Who is sponsoring clinical trial NCT04543253?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04543253 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cushing Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04543253's enrollment target sits among peer trials
700 1st of 9 higher than 9 of 9 other Cushing Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cushing Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome
RECRUITING · Phase 2
-
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
RECRUITING · Phase 1
-
Collecting Information About Treatment Results for Patients With Cushing's Syndrome
RECRUITING
-
Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome
RECRUITING · Phase 2
-
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
ACTIVE NOT RECRUITING · Phase 2
-
Open-label Treatment in Cushing's Syndrome
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900419 · 700 participants
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
- NCT01804686 · 700 participants · Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
- NCT02107989 · 700 participants
Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database
- NCT02129543 · 700 participants
Immune Reconstitution in Stem Cell Transplant Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI